US FDA is urging providers to consider alternatives to paclitaxel-coated devices for the treatment of peripheral arterial disease (PAD) after an agency analysis found the drug-eluting stents and balloons were linked to a higher patient mortality rate.
FDA initially issued an alert about the possible long-term mortality risk in January, after a meta-analysis of randomized trials published...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?